This stock making HUGE waves 🌊

Why I’m excited about its prospects                                                                                                                                                                                                                                                                                                                                                                                                                 April 17, 2023 | [Read Online]( *Sponsored by FSD Pharma. Please see disclosures below. Hey there, it’s me again. I wanted to share a cool biotech stock idea I’ve been tracking recently - FSD Pharma (Nasdaq: HUGE) – and why I’m excited about its prospects. Recently, HUGE issued an announcement about a planned spin-off coming up. This could have major implications for the stock at these levels. There is a very interesting story brewing right now. Make sure you stay up to date on it. The biotech index was down around 2% on the year and starting to perk up, while the Nasdaq was up over 20% and showing signs of topping out. In fact, my recent “Bullseye Trade” idea was a biotech stock, and the options I alerted to my members popped over 270% higher just a few days later. Like I said, we’re on to something BIG right now… possibly even “HUGE” (Sorry, I know it is corny. Such a cool ticker I just have to use it a lot!) I've been following this idea for some time, and I still think it’s worth keeping focus on. Because if you don’t keep paying attention, it’s easy to miss this stock that has quietly made a 17% move higher and hit new 52-week highs last week. And I think that right now we have a small window in time where we can see a massive move in some of the best biotech stocks as they play “catch up” to the bigger indexes. The steady move higher we have seen in HUGE already is a great example of what I am talking about. Here are the major points I think it is important to focus on when looking at FSD Pharma (Nasdaq: HUGE) right now… The stock quietly moved up over 100% to start the year, then went through a consolidation phase for March and just started to break out of that Bull Flag. So, the price action is pretty interesting… but I had to dig into WHY?? FSD Pharma (Nasdaq: HUGE) is an innovative biotech company that is best known for a drug candidate in Phase 1 testing that they hope will treat multiple sclerosis. That is great, but I really felt there had to be something else brewing here. As I started to dig deeper and put the pieces together, I stumbled on something that could be revolutionary. It all started with a [press release]( I read a few weeks ago where they announced that Gerry David was being added to the Board of Advisors. Now, that might not mean a lot to most people, but I have known about Celsius Holdings (Nasdaq: CELH) for years now and traded options on the stock many, many times. In case you don’t know, Gerry David was the Chief Executive Officer of CELH, where he spearheaded a turnaround that resulted in a global sales explosion, influx of capital from notable strategic investors, and a rise in market capitalization that increased shareholder value 35-fold by exceeding $9 billion. In the release, David said (emphases added), “I have seen countless products throughout my career, and I can honestly say that I have never seen anything as unique and disruptive as the product FSD Pharma is developing to counteract alcohol intoxication and misuse.” When I read this, I thought, “Huh?” What is FSD Pharma (Nasdaq: HUGE) working on that would attract the attention of this beverage titan? Going further down the rabbit hole, I read that a few weeks prior to that, Kevin Harrington was also [added to the Advisory Board](. Guess who Gerry worked with as CELH exploded higher over those years? Yep, Kevin & Gerry absolutely crushed it with their last beverage company in one of the all-time greatest … Kevin Harrington is world-renowned as the inventor of the infomercial, pioneer of the “As Seen on TV” brand, and one of the original “Sharks” on the hit ABC show “Shark Tank.” He has launched more than 20 businesses that have each grown sales in excess of $100 million as part of a career that has introduced 1,000+ products generating over $6 billion in global sales. His business experience spans the globe, including opening distribution outlets in over 100 countries. In the release Kevin said, “Throughout my career, my investments have the common thread of ground-floor opportunities in research and development of products that I believe can be transformational, whether it be a beverage, kitchen utensil, or, in the case of FSD Pharma (Nasdaq: HUGE), a strong pipeline of therapeutics, which include potential products that may provide significant help in alcohol misuse cases” (bold added). Then, recently Kevin Harrington posted [this Instagram video]( where he flat out tells everyone how excited he is to be working with FSD Pharma (Nasdaq: HUGE), and makes some bold claims about what he hopes to achieve. Sure enough, when I looked back just a little further, I found a [press release]( from FSD Pharma (Nasdaq: HUGE) talking about a new initiative to potentially reverse the negative effects of alcohol on brain function. From the release…"FSD Pharma’s (Nasdaq: HUGE) existing pipelines and research priorities in brain and inflammatory disorders, including mental health, provides a natural extension to investigate the effects of alcohol on the brain. Our clinical and product development teams are exploring how to limit and potentially reverse the negative effects of alcohol on brain function," said Dr. Lakshmi Kotra (bold added). When you connect all the dots, FSD Pharma (Nasdaq: HUGE) is putting together an all-star advisory team and actively developing something that could be a MASSIVE product. I will keep a close eye on new developments, as we are clearly in the early stages here. If all of this isn’t enough to get you amped up, then check out the technical indicators. Let’s start with [Barchart](. You just can’t get any better than a perfect “100% buy” rating… Then, look at [TipRanks]( which shows an equally impressive rating across all indicators… We are checking all of the boxes when zooming over to [Yahoo]( as well… Great idea, great technicals… now, can they carry this across the finish line? 🏁 Take a [look at the financials](. FSD Pharma (Nasdaq: HUGE) is sitting on over $23 million as of their last filing, with negligible debt. That is a book value over 50% of the current share price! What are they going to do with all that cash besides develop new products? Well, FSD Pharma (Nasdaq: HUGE) [recently said]( its Board of Directors has approved a share repurchase program that will allow the company to buy back up to 1.9 million of its subordinate Class B voting shares over the next 12 months. The 1.9 million shares figure represents about 5% of FSD’s issued and outstanding subordinate voting shares, the company said. I don’t know about you, but I think I am really on to something with FSD Pharma (Nasdaq: HUGE)! There is a potentially massive idea in the works… incredible technicals for the stock price… a stellar balance sheet for a tiny company… and even a share buyback in place! As always, just because I love a stock doesn’t mean you shouldn’t do your own research. I’d suggest you visit their [website]( and learn more about the risks and potential rewards with the company. Best of luck, and do your own due diligence as always! To Your Success, *Please see disclosures below *PAID ADVERTISEMENT. RagingBull has been paid fifteen thousand dollars by ach bank transfer by FSD Pharma for advertising from a period beginning on April 10, 2023 through April 18 of the same year. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, the owners of Raging Bull, do not hold a position in FSD Pharma. This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of FSD Pharma, increased trading volume, and possibly an increased share price of the FSD Pharma securities, which may or may not be temporary and decrease once the marketing arrangement has ended. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for educational and informational purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, Raging Bull can guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision. SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. A portion of our business is engaged in the marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. A portion of RagingBull’s business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our websites, email, SMS, push notifications. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently, companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the corporate awareness program ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at https:// www .sec.gov / edgar/searchedgar/ companysearch TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied. Update your email preferences or unsubscribe [here]( © Boardroom 62 Calef Hwy. #233 Lee, NH 03861, United States [[beehiiv logo]Powered by beehiiv](